Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone.
METHODS: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles. The dual primary end points were event-free survival (the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence, or death) and overall survival. Secondary end points included major pathological response, pathological complete response, and safety.
RESULTS: A total of 397 participants were assigned to the pembrolizumab group, and 400 to the placebo group. At the prespecified first interim analysis, the median follow-up was 25.2 months. Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001). The estimated 24-month overall survival was 80.9% in the pembrolizumab group and 77.6% in the placebo group (P = 0.02, which did not meet the significance criterion). A major pathological response occurred in 30.2% of the participants in the pembrolizumab group and in 11.0% of those in the placebo group (difference, 19.2 percentage points; 95% CI, 13.9 to 24.7; P<0.0001; threshold, P = 0.0001), and a pathological complete response occurred in 18.1% and 4.0%, respectively (difference, 14.2 percentage points; 95% CI, 10.1 to 18.7; P<0.0001; threshold, P = 0.0001). Across all treatment phases, 44.9% of the participants in the pembrolizumab group and 37.3% of those in the placebo group had treatment-related adverse events of grade 3 or higher, including 1.0% and 0.8%, respectively, who had grade 5 events.
CONCLUSIONS: Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.).
| Errataetall: |
CommentIn: Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. - PMID 38090512 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:389 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 389(2023), 6 vom: 10. Aug., Seite 491-503 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wakelee, Heather [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 27.08.2023 Date Revised 26.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT03425643 CommentIn: Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. - PMID 38090512 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2302983 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357745337 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357745337 | ||
| 003 | DE-627 | ||
| 005 | 20240229154336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2302983 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM357745337 | ||
| 035 | |a (NLM)37272513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wakelee, Heather |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2023 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03425643 | ||
| 500 | |a CommentIn: Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. - PMID 38090512 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone | ||
| 520 | |a METHODS: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles. The dual primary end points were event-free survival (the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence, or death) and overall survival. Secondary end points included major pathological response, pathological complete response, and safety | ||
| 520 | |a RESULTS: A total of 397 participants were assigned to the pembrolizumab group, and 400 to the placebo group. At the prespecified first interim analysis, the median follow-up was 25.2 months. Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001). The estimated 24-month overall survival was 80.9% in the pembrolizumab group and 77.6% in the placebo group (P = 0.02, which did not meet the significance criterion). A major pathological response occurred in 30.2% of the participants in the pembrolizumab group and in 11.0% of those in the placebo group (difference, 19.2 percentage points; 95% CI, 13.9 to 24.7; P<0.0001; threshold, P = 0.0001), and a pathological complete response occurred in 18.1% and 4.0%, respectively (difference, 14.2 percentage points; 95% CI, 10.1 to 18.7; P<0.0001; threshold, P = 0.0001). Across all treatment phases, 44.9% of the participants in the pembrolizumab group and 37.3% of those in the placebo group had treatment-related adverse events of grade 3 or higher, including 1.0% and 0.8%, respectively, who had grade 5 events | ||
| 520 | |a CONCLUSIONS: Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Liberman, Moishe |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Terufumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuboi, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Se-Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shugeng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ke-Neng |e verfasserin |4 aut | |
| 700 | 1 | |a Dooms, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Majem, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Eigendorff, Ekkehard |e verfasserin |4 aut | |
| 700 | 1 | |a Martinengo, Gastón L |e verfasserin |4 aut | |
| 700 | 1 | |a Bylicki, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Abreu, Delvys |e verfasserin |4 aut | |
| 700 | 1 | |a Chaft, Jamie E |e verfasserin |4 aut | |
| 700 | 1 | |a Novello, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Steven M |e verfasserin |4 aut | |
| 700 | 1 | |a Samkari, Ayman |e verfasserin |4 aut | |
| 700 | 1 | |a Spicer, Jonathan D |e verfasserin |4 aut | |
| 700 | 0 | |a KEYNOTE-671 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Tatangelo, Marcelo |e investigator |4 oth | |
| 700 | 1 | |a Flores, Marcos |e investigator |4 oth | |
| 700 | 1 | |a Pastor, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Puig, Juan |e investigator |4 oth | |
| 700 | 1 | |a Martinengo, Gaston |e investigator |4 oth | |
| 700 | 1 | |a Varela, Mirta |e investigator |4 oth | |
| 700 | 1 | |a Brocca, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Wong, Mark |e investigator |4 oth | |
| 700 | 1 | |a Hui, Rina |e investigator |4 oth | |
| 700 | 1 | |a Dooms, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Vansteenkiste, Johan |e investigator |4 oth | |
| 700 | 1 | |a Demedts, Ingel |e investigator |4 oth | |
| 700 | 1 | |a Sibille, Anne |e investigator |4 oth | |
| 700 | 1 | |a Surmont, Veerle |e investigator |4 oth | |
| 700 | 1 | |a Deschepper, Koenraad |e investigator |4 oth | |
| 700 | 1 | |a Lambrechts, Marc |e investigator |4 oth | |
| 700 | 1 | |a Dias, Josiane |e investigator |4 oth | |
| 700 | 1 | |a De Marchi, Pedro Rafael Martins |e investigator |4 oth | |
| 700 | 1 | |a Alves, Gustavo |e investigator |4 oth | |
| 700 | 1 | |a Araujo, Luiz Henrique |e investigator |4 oth | |
| 700 | 1 | |a Matias, Danielli |e investigator |4 oth | |
| 700 | 1 | |a Chaves, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Franke, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Teixeira, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Tabacof, Jacques |e investigator |4 oth | |
| 700 | 1 | |a Faria, Luiza |e investigator |4 oth | |
| 700 | 1 | |a Morbeck, Igor |e investigator |4 oth | |
| 700 | 1 | |a Cronemberger, Eduardo Henrique |e investigator |4 oth | |
| 700 | 1 | |a Lima, Iane |e investigator |4 oth | |
| 700 | 1 | |a Sardenberg, Rodrigo |e investigator |4 oth | |
| 700 | 1 | |a de Paiva Junior, Tadeu |e investigator |4 oth | |
| 700 | 1 | |a Dutra, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Guimaraes, Jose Luiz |e investigator |4 oth | |
| 700 | 1 | |a Begin, Paul |e investigator |4 oth | |
| 700 | 1 | |a Langleben, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Liu, Geoffrey |e investigator |4 oth | |
| 700 | 1 | |a Liberman, Moishe |e investigator |4 oth | |
| 700 | 1 | |a Spicer, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Gao, Shugeng |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Guofang |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Tao |e investigator |4 oth | |
| 700 | 1 | |a Yan, Xiaolong |e investigator |4 oth | |
| 700 | 1 | |a Hu, Jian |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jun |e investigator |4 oth | |
| 700 | 1 | |a Tan, Lijie |e investigator |4 oth | |
| 700 | 1 | |a Wang, Qun |e investigator |4 oth | |
| 700 | 1 | |a Li, Shanqing |e investigator |4 oth | |
| 700 | 1 | |a Chen, Keneng |e investigator |4 oth | |
| 700 | 1 | |a Yang, Yue |e investigator |4 oth | |
| 700 | 1 | |a Bai, Jie |e investigator |4 oth | |
| 700 | 1 | |a Ma, Shaohua |e investigator |4 oth | |
| 700 | 1 | |a Chen, Haiquan |e investigator |4 oth | |
| 700 | 1 | |a Chen, Qixun |e investigator |4 oth | |
| 700 | 1 | |a Wang, Wenxiang |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Lanjun |e investigator |4 oth | |
| 700 | 1 | |a Zhu, Yuming |e investigator |4 oth | |
| 700 | 1 | |a Vanakesa, Tonu |e investigator |4 oth | |
| 700 | 1 | |a Zasadny, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Duchemann, Boris |e investigator |4 oth | |
| 700 | 1 | |a Girard, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Bylicki, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Berard, Henri |e investigator |4 oth | |
| 700 | 1 | |a Thiberville, Luc |e investigator |4 oth | |
| 700 | 1 | |a Mennecier, Bertrand |e investigator |4 oth | |
| 700 | 1 | |a Mazieres, Julien |e investigator |4 oth | |
| 700 | 1 | |a Eigendorff, Ekkehard |e investigator |4 oth | |
| 700 | 1 | |a Bonnet, Reiner |e investigator |4 oth | |
| 700 | 1 | |a Fix, Peter |e investigator |4 oth | |
| 700 | 1 | |a Reck, Martin |e investigator |4 oth | |
| 700 | 1 | |a Rittmeyer, Achim |e investigator |4 oth | |
| 700 | 1 | |a Reinacher-Schick, Anke |e investigator |4 oth | |
| 700 | 1 | |a Wehler, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Lehmann, Markus |e investigator |4 oth | |
| 700 | 1 | |a Serke, Monika |e investigator |4 oth | |
| 700 | 1 | |a Wesseler, Claas |e investigator |4 oth | |
| 700 | 1 | |a Täuscher, Dagmar |e investigator |4 oth | |
| 700 | 1 | |a Lang, Susanne |e investigator |4 oth | |
| 700 | 1 | |a Wermke, Martin |e investigator |4 oth | |
| 700 | 1 | |a Grohe, Christian |e investigator |4 oth | |
| 700 | 1 | |a Wirtz, Hubert |e investigator |4 oth | |
| 700 | 1 | |a Kollmeier, Jens |e investigator |4 oth | |
| 700 | 1 | |a Ritgen, Mathias |e investigator |4 oth | |
| 700 | 1 | |a Mueller, Annette |e investigator |4 oth | |
| 700 | 1 | |a Frohling, Klaus-Peter |e investigator |4 oth | |
| 700 | 1 | |a Vogel, Gunther |e investigator |4 oth | |
| 700 | 1 | |a Faehling, Martin |e investigator |4 oth | |
| 700 | 1 | |a Cuffe, Sinead |e investigator |4 oth | |
| 700 | 1 | |a Collins, Dearbhaile |e investigator |4 oth | |
| 700 | 1 | |a Delmonte, Angelo |e investigator |4 oth | |
| 700 | 1 | |a Gilli, Marina |e investigator |4 oth | |
| 700 | 1 | |a Piantedosi, Francovito |e investigator |4 oth | |
| 700 | 1 | |a Ogliari, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Bulotta, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Gregorc, Vanesa |e investigator |4 oth | |
| 700 | 1 | |a Gianni, Luca |e investigator |4 oth | |
| 700 | 1 | |a Grisanti, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Intagliata, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Roca, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Ferrari, Vittorio |e investigator |4 oth | |
| 700 | 1 | |a Berruti, Alfredo |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 389(2023), 6 vom: 10. Aug., Seite 491-503 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:389 |g year:2023 |g number:6 |g day:10 |g month:08 |g pages:491-503 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2302983 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 389 |j 2023 |e 6 |b 10 |c 08 |h 491-503 | ||